Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist

Résumé détaillé

AMB-895 and AMB-131 demonstrate highly differentiated PK profiles and robust efficacy in preclinical models The data were shared as poster presentations at ObesityWeek® 2026…

AMB-895 and AMB-131 demonstrate highly differentiated PK profiles and robust efficacy in preclinical models

BOULDER, Colo., Nov. 15, 2026 /PRNewswire/ -- Ambrosia Biosciences Inc. ("Ambrosia"), today announced nonclinical data in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek® 2026.

AMB-895, a novel oral small molecule GLP-1 receptor agonist intended for once-weekly dosing, demonstrated sustained target coverage greater than EC70 over one week, following a single 1 mg/kg oral dose in lean non-human primates (NHP). AMB-895 also resulted in sustained weight loss and reduced food intake over 14 days of once-weekly oral dosing in a lean NHP model. When dosed at 1 mg/kg, AMB-895 demonstrated 8% mean weight loss from baseline at day 14.

AMB-131, a novel oral small molecule GIP receptor antagonist, demonstrated higher exposure and target coverage at 24 hours in both mouse and NHP models, and enhanced weight loss induced by semaglutide in a mouse model of diet-induced obesity.

"Many treatment options for people with diabetes and obesity are limited by route of administration, tolerability and scalability. There is a significant opportunity to improve the patient experience through novel long-acting oral small molecule therapies that allow for flexibility in dosing and the potential to reduce treatment costs," said Nick Traggis, CEO. "We also believe the future of metabolic disease treatment will include oral combination therapies that can be optimized to balance efficacy and tolerability, and we've designed our small molecule programs with that opportunity in mind.

Ambrosia Biosciences Inc. is a privately held drug discovery company developing next-generation oral small molecule therapies for obesity and other metabolic disorders. By integrating structurally-enabled drug design with in-house medicinal chemistry and biology capabilities, Ambrosia is advancing a complementary pipeline of differentiated therapies.

Forward-Looking StatementThis press…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.